Generic Ozempic in South Africa: what the 2026 patent change means

Is there a generic Ozempic in South Africa?

Yes. SAHPRA approved Sun Pharma's generic semaglutide injection on 15 July 2026, the first registered generic equivalent of Ozempic in South Africa, and the company launched it within a week. It is registered for adults with type 2 diabetes and it remains a Schedule 4 medicine.

The generic comes as a pre-filled, multi-dose pen in two strengths, 2 mg in 1.5 ml and 4 mg in 3 ml, injected once a week. South Africa was the second market worldwide where Sun Pharma secured approval for the product, after India.

It is not alone. Novo Nordisk's own lower-cost copy, Extensior, followed at the end of July, and SAHPRA told Reuters it had twelve further generic semaglutide applications under review. A shelf that held one semaglutide brand for years is becoming a crowded one.

What happened to the semaglutide patent in 2026?

Novo Nordisk's South African patent on semaglutide, the active molecule in Ozempic and Wegovy, expired in March 2026, and Reuters linked the first generic approval directly to that expiry. While the patent stood, no other manufacturer could sell semaglutide here. Once it lapsed, approvals and launches could follow.

A patent is a time-limited monopoly, not a permanent one. Semaglutide's protections lapse across many countries through 2026 and beyond, which is why Indian manufacturers in particular had generic versions ready years in advance.

South Africa sits early in that global wave: the first approval came within four months of the local expiry.

For patients the practical meaning is choice. Until March 2026 one company made every registered semaglutide product in the country; by August there were three registered routes to the same molecule, with more likely to follow.

What is Extensior, the lower-cost Ozempic copy?

Extensior is Ozempic under another name. Novo Nordisk makes it with the same active ingredient, the same manufacturing process and the same pen device, then sells it at a lower price through a partnership with Acino, a Swiss pharmaceutical company. It launched in South Africa at the end of July 2026.

It comes in the same three dose strengths as Ozempic, 0.25 mg, 0.5 mg and 1 mg, injected once a week. SAHPRA registered it as the country's only authorised semaglutide copy, and its registration covers type 2 diabetes, exactly like the original's.

The commercial logic is easy to read. With the patent gone and generics arriving, the originator launched its own cheaper version rather than leave the lower price band to competitors. Novo Nordisk's South African general manager told Reuters that Extensior would cost less than the branded product for type 2 diabetes.

Generic, authorised copy, compounded: what is the difference?

Three very different things get called generic Ozempic in South Africa. A registered generic is an equivalent medicine from another manufacturer, approved by SAHPRA. An authorised copy is the original medicine sold under a second name by its own maker. A compounded copy is an unregistered product with no SAHPRA approval at all.

The first three are lawful medicines that a licensed pharmacy may dispense after a doctor's assessment and authorisation. The fourth is the reason regulators spent 2026 issuing warnings and seizing stock, unpacked in our guide to compounded GLP-1 products in South Africa.

How much cheaper is the generic competition?

The first published figures show a 15% gap. Business Day reported at the end of July 2026 that Extensior's Single Exit Price came in 15% below Ozempic's for the equivalent pens. Sun Pharma had not published a South African price for its generic at the time of writing.

Figures as reported by Business Day in July 2026, VAT included; each pen holds four weekly doses at its labelled strength. We do not sell medicine. Prices vary by pharmacy and dose; confirm with your pharmacy.

The regulated price of every registered medicine is public, generics included: the Department of Health's Medicine Price Registry at mpr.gov.za lists the Single Exit Price by pack, so Sun Pharma's figure will appear there once filed.

One note on reading any of these figures: the till price adds a regulated dispensing fee on top of the Single Exit Price, so two pharmacies can quote slightly different totals on the same pen while the medicine price underneath stays identical.

Can you use generic Ozempic for weight loss?

The registrations say no. Ozempic, Extensior and Sun Pharma's generic are all registered in South Africa for type 2 diabetes. The semaglutide product registered for weight management here is Wegovy, which uses higher doses, and no generic version of Wegovy exists in the country.

Using a diabetes-registered medicine for weight loss is off-label use. Off-label treatment is lawful only as a doctor's considered clinical decision for an individual patient, made during an assessment, never as something a seller may market for that purpose.

That distinction shapes how to read online offers. A seller pushing generic semaglutide for weight loss is promoting an off-label use of a Schedule 4 medicine, which licensed pharmacies and registered practitioners do not do.

Does a generic have the same side effects as Ozempic?

Yes. A registered generic contains the same active molecule at equivalent doses, so it carries the same side effects. Nausea, vomiting, diarrhoea, constipation and stomach discomfort are the common ones, most noticeable in the early weeks and around dose increases, and most cases settle as the body adjusts.

The exclusions travel with the molecule too. Semaglutide is not for use in pregnancy or while breastfeeding, nor by people with a personal or family history of medullary thyroid cancer or MEN2 syndrome, and a history of pancreatitis calls for a careful medical decision. Severe, persistent stomach pain on any semaglutide product can signal pancreatitis: seek medical care immediately.

This is why the Schedule 4 rules do not soften as prices fall. Whichever version a pharmacy dispenses, a doctor's assessment and authorisation comes first, and follow-up matters as much on a generic as on the original.

How many more semaglutide generics are coming?

Twelve applications were under SAHPRA review in July 2026. The regulator confirmed the number to Reuters but named no applicants and gave no timelines, so nobody outside the process knows which company is next or when. What is public: one approval has been granted and a dozen more are queued.

Manufacturers have an obvious incentive to file. Semaglutide is among the most in-demand medicines in the world, and South Africa now has a proven approval route for copies of it.

A longer queue does not mean a lower bar. Each applicant must show SAHPRA the same active ingredient, strength and quality as the original, plus equivalence in how the body absorbs the medicine, before anything reaches a pharmacy shelf.

Registration is not the same as launch, though. Rybelsus, the semaglutide tablet for diabetes, was registered here in 2024 and has still not been launched, so expect each of the twelve to move at its own commercial pace if approved.

Will the Ozempic price come down now?

Movement has already started. Extensior entered 15% below Ozempic's published price, and competition was cutting semaglutide prices before any copy arrived: Reuters reported in March 2026 that Novo Nordisk had reduced Wegovy's South African price for the second time since launch. Pharmacies cannot discount on their own, so change happens at the regulated price itself.

Under the Single Exit Price system, every pharmacy sells a given pack at the same national price, with only a regulated dispensing fee on top. Manufacturers may cut that price, and competition is what makes them: the March 2026 Wegovy adjustment took the lowest dose from R3,090 to R1,873. We do not sell medicine. Prices vary by pharmacy and dose; confirm with your pharmacy.

The pen-by-pen picture for the originator sits in our Ozempic price guide, which tracks the published figures as they move.

Does medical aid cover generic semaglutide?

Cover follows the condition, not the brand. For type 2 diabetes, many schemes fund semaglutide under chronic benefits, and a cheaper registered generic strengthens that case. For weight management, most schemes exclude the medicine class no matter the price, because obesity is not a Prescribed Minimum Benefit condition.

The first generic-era signal kept that line. Business Day reported Discovery Health's response to Extensior's launch: a 15% price cut may make treatment easier to afford out of pocket, but it was unlikely to be enough to justify broader scheme funding, given how many members live with type 2 diabetes.

Scheme rules are re-set each January, so re-check yours at benefit time. What schemes in general do with this class, and what to ask your own, is covered on our medical aid page.

Can the pharmacist swap you onto a generic?

In most cases the pharmacist must offer you the choice. Section 22F of the Medicines Act requires a pharmacist to point out a registered interchangeable generic and the saving it brings, and to dispense it unless the doctor has recorded that no substitute may be used, you decline it, or it would cost more than the original.

The rule exists for exactly this moment: a patent expires, cheaper registered equivalents arrive, and patients get the saving by default rather than by luck. It only applies between registered medicines; nothing sold outside a licensed pharmacy qualifies.

The treatment decision still belongs with your doctor. Dose, monitoring and whether semaglutide suits you at all are settled during the doctor's assessment; the substitution question only arises once a treatment plan exists and a pharmacy dispenses it.

If the pharmacist does not raise it, ask directly at the counter: is there a registered interchangeable generic for this, and what is the price difference?

How do you tell a real generic from a fake one?

A real generic has a SAHPRA registration and reaches you through a licensed pharmacy after a doctor's assessment and authorisation. Anything else sold as generic Ozempic, generic semaglutide or a semaglutide compound, whatever the website or group chat claims, is an unregistered product with unverified contents.

Enforcement through 2026 shows the scale of the problem. Regulators seized unregistered compounded GLP-1 stock in Pretoria in May 2026, and in June a court granted Novo Nordisk an interim order stopping a compounding company from making and selling compounded semaglutide while the dispute continues.

For years SAHPRA's standing warning was that any product claiming to contain semaglutide but not made by Novo Nordisk was likely falsified. Registered generics change that test, but only inside the pharmacy system: check that the seller is a licensed pharmacy and that the product is SAHPRA-registered. Our guide to buying Ozempic online safely walks through those checks step by step.

What does the generic era mean if you are considering treatment?

More registered options and downward pressure on published prices, inside an unchanged clinical process. Semaglutide in any registered form remains a Schedule 4 medicine for a doctor to weigh against your history, your other medicines and your goals. Whether the original, the authorised copy or a generic fits best is decided by a doctor on assessment.

Costs, side effects and the weekly routine deserve the same attention in that conversation as the name on the pen. Outcomes on semaglutide differ from person to person, and individual results vary whichever version a pharmacy dispenses.

Nothing about the generic era changes who suits the molecule and who does not. A cheaper pen is not a reason to start treatment; a clinical need confirmed by a doctor is.

If you want to understand the assessment step itself before going further, how doctor-led treatment works explains what happens and in what order.

Frequently asked questions